Nizatidine: Difference between revisions
remove 'image = {{PAGENAME}}.png' from drugbox, see template talk:drugbox using AWB |
m Replaced chemical formula with new style using AWB |
||
Line 8: | Line 8: | ||
| PubChem = 3033637 |
| PubChem = 3033637 |
||
| DrugBank = APRD00706 |
| DrugBank = APRD00706 |
||
| C=12 | H=21 | N=5 | O=2 | S=2 |
|||
| chemical_formula = C<sub>12</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub> |
|||
| molecular_weight = 331.46 g/mol |
| molecular_weight = 331.46 g/mol |
||
| bioavailability = >70% |
| bioavailability = >70% |
Revision as of 02:08, 25 February 2007
File:Nizatidine.png | |
Clinical data | |
---|---|
License data |
|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >70% |
Protein binding | 35% |
Metabolism | Hepatic |
Elimination half-life | 1-2 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.155.683 |
Chemical and physical data | |
Formula | C12H21N5O2S2 |
Molar mass | 331.46 g/mol g·mol−1 |
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.
Clinical use
Main article: H2-receptor antagonist
Certain preparations of nizatadine are now available over the counter in various countries including the United States.
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.
Nazitidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors.